KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Total Liabilities (2016 - 2026)

Biogen has reported Total Liabilities over the past 18 years, most recently at $10.8 billion for Q1 2026.

  • For Q1 2026, Total Liabilities fell 2.02% year-over-year to $10.8 billion; the TTM value through Mar 2026 reached $10.8 billion, down 2.02%, while the annual FY2025 figure was $11.2 billion, 1.33% down from the prior year.
  • Total Liabilities for Q1 2026 was $10.8 billion at Biogen, down from $11.2 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $13.7 billion in Q3 2023 and troughed at $10.7 billion in Q2 2025.
  • A 5-year average of $11.6 billion and a median of $11.2 billion in 2025 define the central range for Total Liabilities.
  • On a YoY basis, Total Liabilities climbed as much as 13.45% in 2023 and fell as far as 19.08% in 2023.
  • Year by year, Total Liabilities stood at $11.2 billion in 2022, then grew by 7.88% to $12.0 billion in 2023, then decreased by 5.91% to $11.3 billion in 2024, then fell by 1.33% to $11.2 billion in 2025, then decreased by 3.14% to $10.8 billion in 2026.
  • Business Quant data shows Total Liabilities for BIIB at $10.8 billion in Q1 2026, $11.2 billion in Q4 2025, and $11.0 billion in Q3 2025.